146 related articles for article (PubMed ID: 28807232)
21. Targeted therapy in ovarian cancer.
Lim HJ; Ledger W
Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
[TBL] [Abstract][Full Text] [Related]
22. The role of Cediranib in ovarian cancer.
Orbegoso C; Marquina G; George A; Banerjee S
Expert Opin Pharmacother; 2017 Oct; 18(15):1637-1648. PubMed ID: 28933580
[TBL] [Abstract][Full Text] [Related]
23. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
24. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
25. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.
Lee HG; Shin SJ; Chung HW; Kwon SH; Cha SD; Lee JE; Cho CH
J Gynecol Oncol; 2017 Mar; 28(2):e14. PubMed ID: 27894167
[TBL] [Abstract][Full Text] [Related]
26. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
28. Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Duan P; Fan L; Gao Q; Silwal BM; Ren M; Shen Y; Qu W
Curr Drug Targets; 2017; 18(10):1171-1178. PubMed ID: 28443505
[TBL] [Abstract][Full Text] [Related]
29. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
30. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
31. The next steps in improving the outcomes of advanced ovarian cancer.
Openshaw MR; Fotopoulou C; Blagden S; Gabra H
Womens Health (Lond); 2015 Jun; 11(3):355-67. PubMed ID: 26102473
[TBL] [Abstract][Full Text] [Related]
32. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
[TBL] [Abstract][Full Text] [Related]
33. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract][Full Text] [Related]
34. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
35. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
36. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
37. The emerging role of anti-angiogenic therapy in ovarian cancer (review).
Conteduca V; Kopf B; Burgio SL; Bianchi E; Amadori D; De Giorgi U
Int J Oncol; 2014 May; 44(5):1417-24. PubMed ID: 24626312
[TBL] [Abstract][Full Text] [Related]
38. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
Wefers C; Lambert LJ; Torensma R; Hato SV
Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
[TBL] [Abstract][Full Text] [Related]
39. [New drugs and targeted therapeutic agents in ovarian cancer].
de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
[TBL] [Abstract][Full Text] [Related]
40. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
